Company Information

  

Address: 409 ILLINOIS STREET  
City: SAN FRANCISCO 
State: CA 
Zip Code: 94158 
Telephone: 415-978-1200 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a science-based biopharmaceutical company discovering and developing first-in-class therapeutics. Roxadustat (FG-4592), our most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase ("HIF-PH") activity in Phase 3 clinical development for the treatment of anemia in chronic kidney disease ("CKD"). Pamrevlumab (FG-3019), a fully-human monoclonal antibody that inhibits the activity of connective tissue growth factor ("CTGF") is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis ("IPF"), pancreatic cancer, and Duchenne muscular dystrophy ("DMD"). We have taken a global approach to the development and future commercialization of our product candidates, and this includes development and commercialization in the People's Republic of China ("China").  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2017-1.91NAN/E
03/2017-1.05NAN/E
12/2016-0.98NAN/E
09/2016-1.29NAN/E
06/2016-1.63NAN/E
03/2016-1.09NAN/E
12/2015-1.42NAN/E
09/2015-3.07NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.10Total Liab/Total Assets0.67
Net Inc/Total Assets-0.13Total Liab/Inv Cap0.78
Net Inc/Inv Cap-0.15Total Liab/Comm Equity0.50
Pretax Inc/Net Sales-0.34Interest Coverage Ratio-4.76
Net Inc/Net Sales-0.34Curr Debt/EquityNA
Cash Flow/Net Sales0.04LTD/Equity0.62
SG&A/NetSales0.26Total Debt/Equity0.62
Asset Utilization   Liquidity  
Net Receivables Turnover13.89Quick Ratio4.09
Inventory TurnoverNACurrent Ratio4.09
Inventory Day SalesNANet Rec/Curr Assets0.04
Net Sales/Work Cap0.89Inv/Curr AssetsNA
Net Sales/PP&E1.45  

Income Statement (Millions)

  6/30/2017 3/31/2017 12/31/2016 9/30/2016
Total Revenues(Net Sales) 29.00 26.89 31.91 30.10
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 13.43 11.53 12.59 11.65
Operating Income -31.41 -31.37 -31.28 -22.10
Interest Exp 2.76 2.38 2.75 2.76
Pretax Income -33.13 -33.10 -33.81 -24.00
Other Income 1.03 0.65 0.22 0.87
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -33.18 -33.16 -34.00 -24.15

Balance Sheet (Millions)

Assets 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Cash & Short Term Investments 359.40 243.42 253.18 241.81
Receivables - Total 8.93 7.25 10.45 7.69
Inventories - Total NA NA NA NA
Total Current Assets 371.34 256.58 266.52 253.46
Net Property, Plant & Equipment 122.59 122.82 123.66 124.77
Total Assets 542.64 441.76 469.55 486.21
Liabilities        
Accounts Payable 51.80 52.13 57.14 53.79
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 59.77 60.11 65.13 61.74
Long-Term Debt 97.45 97.54 97.35 97.38
Total Liabilities 312.54 310.06 313.71 307.87
Stockholder's Equity        
Minority Interest 19.27 19.27 19.27 19.27
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.71 0.64 0.64 0.63
Retained Earnings -536.09 -502.90 -469.74 -435.74
Treasury Stock NA NA NA NA
Total Stockholders' Equity 230.10 131.70 155.84 178.35
Total Liabilities and Stockholders' Equity 542.64 441.76 469.55 486.21

Cash Flow Summary (Millions)

Categories 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Net Cash Provided by Operating Activities -19.76 -27.14 -18.55 -1.77
Net Cash Provided by Investing Activities 16.92 23.41 -9.12 8.59
Net Cash Provided by Financing Activities 122.46 0.57 3.15 1.09

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/201265.93-32.57--
12/2013102.17-14.94--
12/2014137.60-59.50-3.17
12/2015180.83-85.78-1.42
12/2016179.58-61.68-0.98
Growth Rates28.47----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/1716639,15749.59




Report Date : 10/16/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.